(NASDAQ: ENGN) Engene Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Engene Holdings's revenue in 2025 is $0.On average, 6 Wall Street analysts forecast ENGN's revenue for 2027 to be $1,912,152,201, with the lowest ENGN revenue forecast at $535,582,506, and the highest ENGN revenue forecast at $4,438,946,654. On average, 5 Wall Street analysts forecast ENGN's revenue for 2028 to be $6,035,422,028, with the lowest ENGN revenue forecast at $3,984,672,522, and the highest ENGN revenue forecast at $8,365,921,404.
In 2029, ENGN is forecast to generate $11,795,898,074 in revenue, with the lowest revenue forecast at $9,973,179,975 and the highest revenue forecast at $14,294,124,720.